FGFR2 and non-small cell lung carcinoma: Already, precision oncology has become standard of care in multiple cancers including nonsmall cell lung cancer (NSCLC), BRAF V600E mutated melanoma, fibroblast growth factor receptor 2 (FGFR2) rearranged cholangiocarcinoma, and others [22].